Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Adicet Bio ( (ACET) ).
On October 7, 2025, Adicet Bio received an extension from Nasdaq, allowing the company until April 6, 2026, to meet the minimum bid price requirement of $1.00 per share for continued listing. The company’s stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, and Adicet Bio is considering options like a reverse stock split to regain compliance, with potential delisting if compliance is not achieved.
The most recent analyst rating on (ACET) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Adicet Bio stock, see the ACET Stock Forecast page.
Spark’s Take on ACET Stock
According to Spark, TipRanks’ AI Analyst, ACET is a Underperform.
Adicet Bio faces significant financial challenges and technical weaknesses, with no revenue and ongoing losses as critical concerns. The poor valuation further impacts the stock’s appeal. While the new board appointment is positive, it does not mitigate the substantial risks present in the company’s financials and market performance.
To see Spark’s full report on ACET stock, click here.
More about Adicet Bio
Adicet Bio, Inc. operates in the biotechnology industry, focusing on the development of innovative cell therapies for cancer treatment.
Average Trading Volume: 502,737
Technical Sentiment Signal: Hold
Current Market Cap: $83.25M
See more insights into ACET stock on TipRanks’ Stock Analysis page.